Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review
Immune checkpoint inhibitors (ICIs) belong to a new group of anticancer drugs targeting T-cell proteins involved in the activation of immune response toward malignancies. Their introduction into clinical practice was a milestone in modern cancer treatment. However, the significant advantage of ICIs...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bioscientifica
2020-10-01
|
| Series: | Endocrine Connections |
| Subjects: | |
| Online Access: | https://ec.bioscientifica.com/view/journals/ec/9/10/EC-20-0342.xml |